Evidence map›Paper›PMID 41795805›Full record

ArticleCancer medicine2026

Reduced-Dose Bendamustine as a First-Line Treatment of Follicular Lymphoma Is Associated With Poorer Prognosis.

Keisuke Tanaka, Atsushi Takahata, Yuma Noguchi, Keigo Okada, Tatsuya Saito, Junichi Mukae, Yuki Osada, Ken Suzuki, Daisuke Mizuchi, Koh Yamamoto and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Keisuke TanakaDepartment of Hematology, Institute of Science Tokyo Hospital, Tokyo, Japan.
Atsushi TakahataDepartment of Hematology, Yokosuka Kyosai Hospital, Kanagawa, Japan.ORCID https://orcid.org/0009-0006-7524-9339
Yuma NoguchiDepartment of Hematology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
Keigo OkadaDepartment of Hematology, Ome Medical Center, Tokyo, Japan.
Tatsuya SaitoDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
Junichi MukaeDepartment of Hematology, Tokyo Teishin Hospital, Tokyo, Japan.
Yuki OsadaDepartment of Hematology, The Fraternity Memorial Hospital, Tokyo, Japan.
Ken SuzukiDepartment of Hematology, The Fraternity Memorial Hospital, Tokyo, Japan.
Daisuke MizuchiDepartment of Hematology, Tokyo Teishin Hospital, Tokyo, Japan.
Koh YamamotoDepartment of Hematology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan.
Takashi KumagaiDepartment of Hematology, Ome Medical Center, Tokyo, Japan.
Gaku OshikawaDepartment of Hematology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.
Takehiko MoriDepartment of Hematology, Institute of Science Tokyo Hospital, Tokyo, Japan.
Shigeo ToyotaDepartment of Hematology, Yokosuka Kyosai Hospital, Kanagawa, Japan.
Masahide YamamotoDepartment of Hematology, Institute of Science Tokyo Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The dose of bendamustine used to treat previously untreated follicular lymphoma (FL) is sometimes reduced based on various clinical considerations, but the impact of such dose reductions on outcomes is unclear. We retrospectively analyzed 92 untreated FL patients treated with bendamustine at seven institutions in Japan. Dose reduction was defined as receiving less than 90% of the planned total dose of 1080 mg/m

Indexed as

Antineoplastic Agents, AlkylatingBendamustine HydrochlorideLymphoma, FollicularAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntineoplastic Agents, AlkylatingBendamustine Hydrochloridebendamustinedose‐reductionfollicular lymphoma

Identifiers

PMID41795805
PMCPMC12967496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.